Main Highlights
1. Syringe maker Catalent suggested soaring demand for injectable weight-loss drugs could lead to sizable revenue gains, and shares surged.
2. The company said sales of its pre-filled syringes could increase more than five-fold because of the popularity of those drugs.
3. Catalent also released preliminary quarterly results, and revenue exceeded...
Analyzing the options chain and the chart patterns of CTLT Catalent prior to the earnings report this week,
I would consider purchasing the 40usd strike price in the money Calls with
an expiration date of 2024-1-19,
for a premium of approximately $8.30.
If these options prove to be profitable prior to the earnings release, I would sell at least half of...
Catalent - 30d expiry - We look to Sell a break of 65.98 (stop at 69.98)
We have a Gap open at 6.2. from 56.05 to 69.46.
The primary trend remains bearish.
A break of support at 66.44 should lead to a more aggressive move lower towards 55.00.
This stock has seen poor sales growth.
Our outlook is bearish.
Our profit targets will be 55.98 and 53.98...
Now I've been watching Catalent, since they partnered up with one of the stocks I hold for a COVID treatment. Novan. Doing a quick glance at CTLT I noticed a TA pattern known as a double bottom and with certain catalyst coming out, maybe its about to run up and leave this bearish trend.
News
-ER is in 14 days
-They have partnered up with Novan to design the...
